United States Plaque Psoriasis Market
Plaque psoriasis is the most prevalent type of psoriasis, an autoimmune skin condition that presents with red, elevated, and scaly patches. The disease has a high prevalence among the U.S. population, with growing incidence attributed to genetic, environmental, and lifestyle factors. The United States Plaque Psoriasis Market is experiencing significant growth because of the increased use of biologic therapies, sophisticated systemic therapies, and greater healthcare awareness. Market size growth is facilitated through robust R&D efforts, new product approvals, and expanding patient population. The existing market situation demonstrates high demand for targeted therapies, such as IL-17 and IL-23 inhibitors, and a heightened trend toward personalized treatment strategies.

Market Segmentation
By Treatment Type
•    Topical Treatments
o    Corticosteroids
    High-Potency Steroids
    Low-Potency Steroids
    Others
o    Vitamin D Analogs
    Calcipotriol
    Calcitriol
o    Others
•    Systemic Treatments
o    Biologic Therapies
    TNF Inhibitors
    IL-17 Inhibitors
    IL-23 Inhibitors
o    Traditional Systemic Drugs
    Methotrexate
    Cyclosporine
    Acitretin
•    Phototherapy
o    Narrowband UVB
o    PUVA Therapy
•    Others

By Severity
•    Mild Plaque Psoriasis
o    Topical Therapy-Based Treatment
o    Phototherapy-Based Treatment
•    Moderate-to-Severe Plaque Psoriasis
o    Systemic Drug-Based Treatment
o    Biologic Therapy-Based Treatment
•    Others

By Distribution Channel
•    Hospital Pharmacies
o    Dermatology Clinics
o    Specialty Pharmacies
•    Retail Pharmacies
o    Independent Pharmacies
o    Chain Pharmacies
•    Online Pharmacies
o    E-Commerce Platforms
o    Direct-to-Consumer Sales

By Patient Demographics
•    Adults
o    Young Adults
o    Middle-Aged Adults
o    Seniors
•    Pediatric Patients
o    Children
o    Adolescents
•    Others

List of Market Players
•    AbbVie Inc. (United States)
•    Amgen Inc. (United States)
•    Eli Lilly and Company (United States)
•    Pfizer Inc. (United States)
•    Johnson & Johnson (United States)
•    Novartis AG (Switzerland)
•    UCB S.A. (Belgium)
•    Bristol-Myers Squibb (United States)
•    Sun Pharmaceutical Industries Ltd. (India)
•    Biogen Inc. (United States)
•    Sanofi S.A. (France)
•    Takeda Pharmaceutical Company (Japan)
•    Galderma S.A. (Switzerland)
•    Merck & Co., Inc. (United States)
•    Dermavant Sciences (United States)

Market Drivers
The United States Psoriasis Plaques Market is growing due to increased cases of psoriasis and improved treatment options. The introduction of biologic medications like IL-17 and IL-23 inhibitors has transformed patient treatment. Further, escalating research in targeted immune-modulating medicines is fueling market growth. Meanwhile, growing expenditures on healthcare and on-the-spot awareness of patients about effective treatment measures have also dramatically increased demand in the market. Additionally, approvals by the FDA of innovative medicines and new biologics on the block provide affordable versions for costly biologics that push market growth.

Market Restraints
Notwithstanding its expansion, the market has pitfalls such as high biologic prices and sparse insurance coverage for innovative treatments. Certain biologic treatments have side effects, for instance, susceptibility to infections, making patients shy away. Also, strict approval from regulatory bodies of new medicines slows down market growth. The presence of alternative drugs, including natural medication and over-the-counter topical remedies, also contributes to the revenue decline of the market.

Market Opportunities
The growing emphasis on precision medicine and customized treatment strategies offers a major opportunity for market participants. Drug makers are investing in R&D to develop safer and more efficient treatments, such as gene therapy and new small-molecule drugs. Growth of digital healthcare solutions, like telemedicine and online pharmacies, is also driving the market. In addition, partnerships among biotech companies and research institutes to create new biologics and biosimilars hold promising opportunities.

Market Trends
One of the most recent trends in the United States Plaque Psoriasis Market is increased use of biologic therapies over conventional systemic treatments. Patients and physicians alike prefer biologics owing to better efficacy and a better safety profile. The rise of JAK inhibitors as a replacement for biologics is on the rise. Furthermore, breakthroughs in topical treatments, such as non-steroid-based treatments, are offering new possibilities for psoriasis control. Pharmaceutical firms are also investing in AI-based drug discovery to improve treatment outcomes.

Approved Products & Pipeline
 • Approved Products: Skyrizi (Risankizumab), Tremfya (Guselkumab), Taltz (Ixekizumab), Cosentyx (Secukinumab), Stelara               (Ustekinumab), Humira (Adalimumab)
 • Pipeline Products: Bimekizumab, Mirikizumab, JAK Inhibitors (Tofacitinib, Baricitinib)

Key Target Audience
•    Pharmaceutical Companies
•    Dermatologists & Healthcare Providers
•    Biotech Research Firms
•    Investors & Venture Capitalists
•    Government & Regulatory Agencies
•    Healthcare Insurers & Payers
•    Academic & Research Institutions
•    Online and Retail Pharmacies

FAQs